Theralink® Technologies Announces an Update on its Securities
Theralink Technologies (OTC: OBMP) announced a significant update regarding its securities on October 22, 2021. The company is currently unable to issue new shares of its common stock, pending approval from FINRA for a name change to 'Theralink Technologies, Inc.' and a new ticker symbol 'THER'. This change is essential for the issuance of new common stock under a new CUSIP. Theralink specializes in precision medicine and molecular profiling, particularly in oncology, with a focus on improving cancer outcomes through its patented biomarker platform.
- Theralink is advancing towards a name and ticker symbol change, which may enhance market visibility.
- The company's focus on precision oncology could attract more investment opportunities.
- Current inability to issue new shares may limit immediate capital-raising opportunities.
- Dependence on FINRA approval introduces uncertainty in timeline for securities issuance.
DENVER, Oct. 22, 2021 /PRNewswire/ -- Theralink Technologies (OTC: OBMP) ("Theralink" or the "Company"), a precision medicine molecular profiling company with a novel phosphoprotein-based Laboratory Developed Test (LDT), today announced an update on its securities. At this time, Theralink is unable to issue new shares of its common stock. The company has applied to the Financial Industry Regulatory Authority, Inc. ("FINRA") to have its name changed to "Theralink Technologies, Inc.," and ticker symbol changed to "THER". FINRA is presently reviewing our corporate action filing. Upon the completion of FINRA's review and its approval of our name change and ticker symbol change, we will be able to issue new shares of common stock under a new CUSIP. We will provide an additional update upon occurrence of the same.
About Theralink Technologies, Inc.
Theralink Technologies is a proteomics-based, molecular profiling and precision medicine company with a CLIA-certified laboratory located in Golden, Colorado. Through its unique and patented phosphoprotein and protein biomarker platform and LDTs, Theralink's technology targets multiple areas of oncology and drug development. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. Theralink intends to help improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.
Forward-Looking Statements
Certain statements contained in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, anything relating or referring to future financial results, patient enrollment and plans for future business development activities, and are thus prospective. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified based on current expectations. Such risks and uncertainties include, without limitation, the risks and uncertainties set forth from time to time in reports filed by Theralink Technologies with the Securities and Exchange Commission. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business and although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements contained herein. The company undertakes no obligation to publicly release statements made to reflect events or circumstances after the date hereof.
View original content:https://www.prnewswire.com/news-releases/theralink-technologies-announces-an-update-on-its-securities-301406928.html
SOURCE Theralink Technologies
FAQ
What recent updates did Theralink Technologies provide regarding its securities?
What is Theralink Technologies' new ticker symbol?
What is the significance of Theralink's name change?
Why is Theralink unable to issue new shares?
